Novavax, Inc. (NASDAQ:NVAX) is one of the top long-term biotechnology stocks to buy. On October 24, Cantor Fitzgerald ...

There is decreased risk for hospitalization in patients with heart failure who receive a high-dose inactivated influenza vaccine.

GSK raised its 2025 sales and earnings forecasts on Wednesday as its speciality HIV and cancer drugs posted double digit ...

The coming flu season is the clearest indication yet that biopharma’s long-standing assumptions about predictability, ...

Sanofi successfully prices USD 3billion of bond issue Paris, France – October 28, 2025 - Sanofi announces that it has successfully priced its ...

(Reuters) -Australian biotech CSL on Tuesday delayed its planned vaccine division spin-off and cut earnings forecasts due to a bigger-than-expected decline in U.S. flu vaccination rates, sending its ...

Sanofi’s Q3 saw total revenues rise 7% CER, with Dupixent contributing over €4 billion for the first time. Click here to read ...

Dupixent’s Q3 sales increased by 26.2%, breaking through the €4bn ceiling for the first time in a single quarter.

Over the last 13 months, Sanofi and Regeneron have revved up the momentum for Dupixent, gaining three new indications for the ...

The French pharma’s overall vaccine sales declined 8% in the quarter, with a key driver being slower-than-usual uptake of flu ...

Patients with untreated advanced melanoma do not appear to gain a survival advantage from the addition of a cancer vaccine to pembrolizumab, suggests a trial.

Sanofi Q3 sales beat estimates on strong Dupixent and new drug demand; reaffirms 2025 outlook with double-digit EPS growth ...